We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




Diagnostic Efficacy of Immunomarkers in Fungal Bloodstream Infection

By LabMedica International staff writers
Posted on 05 Feb 2020
Print article
Image: The MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel - Premixed 30 Plex - Immunology Multiplex Assay (Photo courtesy of Merck).
Image: The MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel - Premixed 30 Plex - Immunology Multiplex Assay (Photo courtesy of Merck).
Fungemia is the presence of fungi or yeasts in the blood and is a life‐threatening condition with the global mortality rate surging more than fivefold in the past decade. It has been reported that the outcome depends on early and targeted treatment; thus, prompt diagnosis is essential at the early stage of infection.

Currently, early diagnosis of fungemia remains a complicated issue. Although blood culture remains the reference method for the detection of fungemia, this method takes 3‐5 days to generate positive results and also suffers from low sensitivity, which could not meet the requirement of early diagnosis and clinical guidance for fungemia.

Clinical Laboratory scientists at the Chinese PLA General Hospital (Beijing, China) included in their study 41 patients with fungemia who were compared with 57 patients with negative blood culture results. Blood samples for culture were taken from the patients for two to three times and inoculated using BACTEC PLUS Aerobic/F (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) blood culture bottles. The isolations from blood culture were identified to species with VETIK YBC card (bioMérieux, Marcy-l'Étoile, France) and bioMérieux MALDI‐TOF‐MS.

The serum samples were analyzed using the xMAP Bead Array Platform (Luminex Corporation, Austin, TX, USA). A combination of 14 cytokines and chemokines was quantified using the reagents of selected ones from Human Cytokine 30‐Plex Panel Kit (Merck-Millipore, Burlington, MA, USA). Evaluated cytokines included the following: IL‐1β, ‐2, ‐3, ‐4, ‐6, ‐8, 10, 17, 12p70, INF‐γ, TNF‐α, G‐CSF, RANTES, and MIP‐1β. C-reactive protein (CRP) was measured using nephelometric method (Siemens BNII, Cardiophase, Erlangen, Germany), and procalcitonin (PCT) was measured by cobas 800 (Roche, Basel Switzerland) based on electrochemical luminescence technology.

The scientists reported that C‐reactive protein and procalcitonin were significantly higher compared with those in negative control group, while white blood cell, percentage of neutrophil, percentage of lymphocyte, and ratio of neutrophil and lymphocyte did not differentiate between two groups. Serum levels of IFN‐γ, TNF‐α, MIP‐1β, IL‐6, IL‐8, IL‐10, IL‐12p70, and IL‐17 were significantly higher in patients with fungemia compared with the control group. Combination of MIP‐1β and IL‐17 could improve the AUC, sensitivity, and specificity for the diagnosis of fungemia.

The authors concluded that they had found eight serum cytokines/chemokines that significantly increased in the fungemia group when compared with the culture‐negative control group. Among them, MIP‐1β and IL‐17 might be given more attention during the diagnosis of fungemia. The study was published on January 23, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Chinese PLA General Hospital
Becton, Dickinson and Company
Merck-Millipore
bioMérieux
Luminex Corporation
Siemens
Roche


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.